Literature DB >> 18196579

Second primary neoplasms in survivors of Wilms' tumour--a population-based cohort study from the British Childhood Cancer Survivor Study.

Aliki J Taylor1, David L Winter, Kathy Pritchard-Jones, Charles A Stiller, Clare Frobisher, Emma R Lancashire, Raoul C Reulen, Mike M Hawkins.   

Abstract

A British population-based cohort study was carried out to determine the risk of second primary neoplasms in survivors of Wilms' tumour. The cohort was obtained from the British Childhood Cancer Survivor Study, a population-based cohort study of treatment toxicities in 18,044 individuals diagnosed with childhood cancer, at an age of less than 15 years, between 1940 and 1991 in Britain. There were 1,441 Wilms' tumour survivors in the cohort: 732 males (50.8%) and 709 females (49.2%). Total follow-up from 5-year survival was 27,841 person years, mean follow-up of 19.3 years per survivor. There were 81 second primary neoplasms, including 52 solid neoplasms, 3 acute myeloid leukaemias and 26 basal cell carcinomas. Thirty-five of the 39 solid neoplasms that developed in the thoracic, abdominal or pelvic region occurred within irradiated tissue. The standardised incidence ratio for all solid second primary neoplasms was 6.7 (95% CI: 5.0-8.8). Cumulative incidence for all solid second primary neoplasms by ages 30, 40 and 50 years was 2.3% (1.4-3.5%), 6.8% (4.6-9.5%) and 12.2% (7.3-18.4%). The overall risk of second primary neoplasms in survivors of Wilms' tumour treated between 1940 and 1991 was substantial, and solid second tumours tended to develop in the irradiated tissue. Continued follow-up of these survivors is important to monitor such late effects of treatment. It is also important to evaluate the risk of second primary neoplasms following more recent lower radiation dose treatment practices. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2008        PMID: 18196579     DOI: 10.1002/ijc.23333

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  19 in total

1.  Outcomes of children with favorable histology wilms tumor and peritoneal implants treated in National Wilms Tumor Studies-4 and -5.

Authors:  John A Kalapurakal; Daniel M Green; Gerald Haase; James R Anderson; Jeffrey S Dome; Paul E Grundy
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-06-01       Impact factor: 7.038

2.  Best of the AUA Annual Meeting: Highlights From the 2011 American Urological Association Meeting, May 14-19, 2011, Washington, DC.

Authors:  Michael K Brawer; Stacy Loeb; Alan W Partin; Jayabalan Nirmal; Michael B Chancellor; J Curtis Nickel; Jacob Rajfer; Ellen Shapiro; Claus G Roehrborn
Journal:  Rev Urol       Date:  2011

3.  Secondary neoplasms after Wilms' tumor in Germany.

Authors:  Nasenien Nourkami; Rhoikos Furtwängler; Muhannad Alkassar; Norbert Graf
Journal:  Strahlenther Onkol       Date:  2009-08       Impact factor: 3.621

4.  Second malignant neoplasms among children, adolescents and young adults with Wilms tumor.

Authors:  Jean S Lee; Benjamin Padilla; Steven G DuBois; Aris Oates; John Boscardin; Robert E Goldsby
Journal:  Pediatr Blood Cancer       Date:  2015-03-25       Impact factor: 3.167

5.  β-Catenin and K-RAS synergize to form primitive renal epithelial tumors with features of epithelial Wilms' tumors.

Authors:  Peter E Clark; Dina Polosukhina; Harold Love; Hernan Correa; Cheryl Coffin; Elizabeth J Perlman; Mark de Caestecker; Harold L Moses; Roy Zent
Journal:  Am J Pathol       Date:  2011-10-08       Impact factor: 4.307

6.  Updated Breast Cancer Surveillance Recommendations for Female Survivors of Childhood, Adolescent, and Young Adult Cancer From the International Guideline Harmonization Group.

Authors:  Renée L Mulder; Melissa M Hudson; Smita Bhatia; Wendy Landier; Gill Levitt; Louis S Constine; W Hamish Wallace; Flora E van Leeuwen; Cécile M Ronckers; Tara O Henderson; Chaya S Moskowitz; Danielle N Friedman; Andrea K Ng; Helen C Jenkinson; Charlotte Demoor-Goldschmidt; Roderick Skinner; Leontien C M Kremer; Kevin C Oeffinger
Journal:  J Clin Oncol       Date:  2020-09-29       Impact factor: 44.544

7.  Colonic adenocarcinoma as a secondary malignancy after treatment of embryonal rhabdomyosarcoma.

Authors:  Moustafa Hamchou; Hilal Matta; Gabriel Ionescu; Adnan Swid; Ahmed H Al-Salem
Journal:  World J Pediatr       Date:  2011-08-27       Impact factor: 2.764

Review 8.  Pediatric genitourinary tumors.

Authors:  Sharon M Castellino; Anibal R Martinez-Borges; Thomas W McLean
Journal:  Curr Opin Oncol       Date:  2009-05       Impact factor: 3.645

9.  Secondary malignant neoplasms after Wilms tumor: an international collaborative study.

Authors:  Norman E Breslow; Jane M Lange; Debra L Friedman; Daniel M Green; Mike M Hawkins; Michael F G Murphy; Joseph P Neglia; Jørgen H Olsen; Susan M Peterson; Charles A Stiller; Leslie L Robison
Journal:  Int J Cancer       Date:  2010-08-01       Impact factor: 7.396

10.  Hepatic metastasis at diagnosis in patients with Wilms tumor is not an independent adverse prognostic factor for stage IV Wilms tumor: a report from the Children's Oncology Group/National Wilms Tumor Study Group.

Authors:  Peter F Ehrlich; Fernando A Ferrer; Michael L Ritchey; James R Anderson; Daniel M Green; Paul E Grundy; Jeffrey S Dome; John A Kalapurakal; Elizabeth J Perlman; Robert C Shamberger
Journal:  Ann Surg       Date:  2009-10       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.